Related references
Note: Only part of the references are listed.Mechanisms of proteasome inhibitor action and resistance in cancer
David J. McConkey et al.
DRUG RESISTANCE UPDATES (2008)
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelorna
Deborah J. Kuhn et al.
BLOOD (2007)
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome
Susan D. Demo et al.
CANCER RESEARCH (2007)
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Esther A. Obeng et al.
BLOOD (2006)
Phase III study of PSC-833 (Valspodar) in combination with vincristine, doxorubicin, and dexamethasone (Valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95) - A Trial of the Eastern Cooperative Oncology Group
WR Friedenberg et al.
CANCER (2006)
Treatment of multiple myeloma: An emphasis on new developments
RA Kyle et al.
ANNALS OF MEDICINE (2006)
Overcoming drug resistance in multiple myeloma: The emergence of therapeutic approaches to induce apoptosis
HH Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
The proteasome: a novel target for cancer chemotherapy
JB Almond et al.
LEUKEMIA (2002)
Share Paper
